EUCTR2018-002264-57-HU进行中（未招募）1 期
A Multicenter, Randomized, Double-Blind, Double-Dummy, Active Controlled Study Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Adult Subjects with Moderate to Severe Atopic Dermatitis - Heads UP
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 650
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female subjects between 18 years old and 75 years old
- •Active moderate to severe atopic dermatitis defined by EASI, IGA, BSA, and pruritus
- •Candidate for systemic therapy or have recently required systemic therapy for atopic dermatitis
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 600
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •Prior exposure to any JAK inhibitor or Dupilumab
- •Unable or unwilling to discontinue current AD treatments prior to the study
- •Requirement of prohibited medications during the study
- •Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions
- •Female subject who is pregnant, breastfeeding, or considering pregnancy during the study
研究者
相似试验
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Evaluating the Effects of 2 Different Regimens of Montelukast (Daily Dosing and Intermittent, Episode-Driven Dosing) Compared with Placebo in the Treatment of Episodic Asthma in Children Aged 2 to 5 Years - Intermittent and Daily Treatment for Episodic Asthma (IDEA)episodic or intermittent asthmaMedDRA version: 8.1 Level: LLT Classification code 10003553 Term: AsthmaEUCTR2006-002791-18-FISuomen MSD Oy1,771
进行中（未招募）
不适用
A study involving an experimental drug named elvitegravir for the treatment of HIV-1 infection. The experimental drug or its comparator, named raltegravir, will be given in combination with a background regimen in subjects who are failing their current regimen of HIV medications. The first part of the study is a double-blind study, which means that neither you nor your study doctor will know which study drug you are receiving.MedDRA version: 15.0Level: LLTClassification code 10020192Term: HIV-1System Organ Class: 10021881 - Infections and infestationsHuman Innunodeficiency Virus (HIV-1) InfectionsEUCTR2007-004225-26-DEGilead Sciences Incorporated700
进行中（未招募）
1 期
Clinical trial investigating the efficacy and safety of investigational drug TEV-48125 developed to prevent chronic cluster headacheChronic Cluster headache (CCH)MedDRA version: 20.0Level: LLTClassification code 10009698Term: Cluster headachesSystem Organ Class: 100000004852EUCTR2016-003171-21-PLTeva Branded Pharmaceutical Products R&D, Inc.300
进行中（未招募）
1 期
A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel group, Dose Response Study of subcutaneous AVE5026 with an Enoxaparin Calibrator Arm in the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Knee Replacement Surgery - TREKPatients undergoing elective total knee replacement surgery (risk of venous thromboembolic event)MedDRA version: 8.1Level: LLTClassification code 10049909EUCTR2005-006202-26-DKSanofi-Synthelabo Recherche800
进行中（未招募）
不适用
A Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Study Evaluating the Effects of 2 Different Regimens of Montelukast (Daily Dosing and Intermittent, Episode-Driven Dosing) Compared With Placebo in the Treatment of Episodic Asthma in Children Aged 6 Months to 5 Years - Intermittent and Daily Treatment for Episodic Asthma (IDEA)episodic or intermittent asthma (not chronic asthma)MedDRA version: 8.1Level: LLTClassification code 10003553Term: AsthmaEUCTR2006-002791-18-LTMerck & Co., Inc.1,700